318 related articles for article (PubMed ID: 1377948)
41. Immunogenic potential of rgp120 from African HIV-1 subtype A.
Xie JM; Pestano GA; Samms M; Lee SK; Guyden J; Boto WM
Vaccine; 1996 Jul; 14(10):993-1000. PubMed ID: 8873394
[TBL] [Abstract][Full Text] [Related]
42. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1.
Zwart G; Wolfs TF; Valk M; Van der Hoek L; Kuiken CL; Goudsmit J
AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1897-908. PubMed ID: 1489578
[TBL] [Abstract][Full Text] [Related]
43. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
44. Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB.
Nehete PN; Murthy KK; Satterfield WC; Arlinghaus RB; Sastry KJ
AIDS; 1995 Jun; 9(6):567-72. PubMed ID: 7662194
[TBL] [Abstract][Full Text] [Related]
45. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
46. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
47. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
Nara PL; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Gallo RC; Fischinger PJ; Goudsmit J
J Virol; 1990 Aug; 64(8):3779-91. PubMed ID: 2370681
[TBL] [Abstract][Full Text] [Related]
48. Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil.
Bongertz V; Morgado MG; Galvão-Castro B; Wigzell H; Hendry RM
Mem Inst Oswaldo Cruz; 1994; 89(1):113-4. PubMed ID: 7823807
[TBL] [Abstract][Full Text] [Related]
49. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.
von Brunn A; Brand M; Reichhuber C; Morys-Wortmann C; Deinhardt F; Schödel F
Vaccine; 1993; 11(8):817-24. PubMed ID: 7689283
[TBL] [Abstract][Full Text] [Related]
50. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
51. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
[TBL] [Abstract][Full Text] [Related]
52. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
53. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
54. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.
Eda Y; Takizawa M; Murakami T; Maeda H; Kimachi K; Yonemura H; Koyanagi S; Shiosaki K; Higuchi H; Makizumi K; Nakashima T; Osatomi K; Tokiyoshi S; Matsushita S; Yamamoto N; Honda M
J Virol; 2006 Jun; 80(11):5552-62. PubMed ID: 16699036
[TBL] [Abstract][Full Text] [Related]
55. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):631-5. PubMed ID: 7831341
[TBL] [Abstract][Full Text] [Related]
56. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study.
Parekh BS; Shaffer N; Pau CP; Abrams E; Thomas P; Pollack H; Bamji M; Kaul A; Schochetman G; Rogers M
AIDS; 1991 Oct; 5(10):1179-84. PubMed ID: 1786145
[TBL] [Abstract][Full Text] [Related]
57. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
[TBL] [Abstract][Full Text] [Related]
58. Comparing antigenicity and immunogenicity of engineered gp120.
Selvarajah S; Puffer B; Pantophlet R; Law M; Doms RW; Burton DR
J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
[TBL] [Abstract][Full Text] [Related]
59. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.
Zwart G; Langedijk H; van der Hoek L; de Jong JJ; Wolfs TF; Ramautarsing C; Bakker M; de Ronde A; Goudsmit J
Virology; 1991 Apr; 181(2):481-9. PubMed ID: 2014634
[TBL] [Abstract][Full Text] [Related]
60. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.
Moore PL; Gray ES; Choge IA; Ranchobe N; Mlisana K; Abdool Karim SS; Williamson C; Morris L;
J Virol; 2008 Feb; 82(4):1860-9. PubMed ID: 18057243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
